AR050851A1 - Conjugados de hormona del crecimiento humana y polietilenglicol ramificado con glicerol, proceso para su preparacion y metodos de uso de los mismos - Google Patents

Conjugados de hormona del crecimiento humana y polietilenglicol ramificado con glicerol, proceso para su preparacion y metodos de uso de los mismos

Info

Publication number
AR050851A1
AR050851A1 ARP050103612A ARP050103612A AR050851A1 AR 050851 A1 AR050851 A1 AR 050851A1 AR P050103612 A ARP050103612 A AR P050103612A AR P050103612 A ARP050103612 A AR P050103612A AR 050851 A1 AR050851 A1 AR 050851A1
Authority
AR
Argentina
Prior art keywords
growth hormone
human growth
glicerol
ramified
polyethylenglycol
Prior art date
Application number
ARP050103612A
Other languages
English (en)
Spanish (es)
Original Assignee
Upjohn Company Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=35708806&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR050851(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Upjohn Company Llc filed Critical Upjohn Company Llc
Publication of AR050851A1 publication Critical patent/AR050851A1/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22Hormones
    • A61K38/27Growth hormone [GH], i.e. somatotropin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • A61P15/06Antiabortive agents; Labour repressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10Drugs for genital or sexual disorders; Contraceptives for impotence
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/08Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/08Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/02Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/06Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Endocrinology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Reproductive Health (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Psychiatry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
ARP050103612A 2004-08-31 2005-08-29 Conjugados de hormona del crecimiento humana y polietilenglicol ramificado con glicerol, proceso para su preparacion y metodos de uso de los mismos AR050851A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US60594504P 2004-08-31 2004-08-31

Publications (1)

Publication Number Publication Date
AR050851A1 true AR050851A1 (es) 2006-11-29

Family

ID=35708806

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP050103612A AR050851A1 (es) 2004-08-31 2005-08-29 Conjugados de hormona del crecimiento humana y polietilenglicol ramificado con glicerol, proceso para su preparacion y metodos de uso de los mismos

Country Status (24)

Country Link
EP (1) EP1789092A2 (ru)
JP (1) JP2008511610A (ru)
KR (1) KR20070042567A (ru)
CN (1) CN101010105A (ru)
AP (1) AP2007003919A0 (ru)
AR (1) AR050851A1 (ru)
AU (1) AU2005278903A1 (ru)
BR (1) BRPI0515118A (ru)
CA (1) CA2577999A1 (ru)
CR (1) CR8942A (ru)
EA (1) EA200700380A1 (ru)
EC (1) ECSP077281A (ru)
GT (1) GT200500235A (ru)
IL (1) IL181085A0 (ru)
MA (1) MA28908B1 (ru)
MX (1) MX2007002441A (ru)
NL (1) NL1029828C2 (ru)
NO (1) NO20071322L (ru)
PE (1) PE20060654A1 (ru)
TN (1) TNSN07078A1 (ru)
TW (1) TW200621291A (ru)
UY (1) UY29088A1 (ru)
WO (1) WO2006024953A2 (ru)
ZA (1) ZA200701802B (ru)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69838552T2 (de) 1997-07-14 2008-05-21 Bolder Biotechnology, Inc., Louisville Derivate des wachstumshormons und verwandte proteine
US7495087B2 (en) 1997-07-14 2009-02-24 Bolder Biotechnology, Inc. Cysteine muteins in the C-D loop of human interleukin-11
EP2305804B1 (en) 1999-01-14 2015-05-06 Bolder Biotechnology, Inc. MonoPEGylated human growth hormone
US7855279B2 (en) 2005-09-27 2010-12-21 Amunix Operating, Inc. Unstructured recombinant polymers and uses thereof
EP1834963A1 (en) * 2006-03-13 2007-09-19 Siegfried Ltd. Di-polymer protein conjugates and processes for their preparation
US20090117077A1 (en) * 2006-05-12 2009-05-07 Dong-A Pharm. Co., Ltd. Polyethylene glycol-interferon alpha conjugate
JP2008069073A (ja) * 2006-09-12 2008-03-27 Yokohama Tlo Co Ltd ラクトフェリン複合体及びその製造方法
KR101079993B1 (ko) * 2006-11-17 2011-11-04 동아제약주식회사 폴리에틸렌글리콜 과립구 콜로니 자극인자 접합체
CL2008002399A1 (es) 2007-08-16 2009-01-02 Pharmaessentia Corp Conjugado sustancialmente puro que posee una porcion polimerica, una porcion proteica (interferon alfa 2b) y un ligante alifatico de 1 a 10 atomos de carbono, util en el tratamiento de las hepatitis b o c.
EP2300501B1 (en) * 2008-07-23 2014-08-20 Hanmi Science Co., Ltd. A polypeptide complex comprising non-peptidyl polymer having three functional ends
EA020347B1 (ru) 2008-07-31 2014-10-30 Фармаиссэншиа Корп. Пептид-полимерные конъюгаты
US8535655B2 (en) 2008-10-10 2013-09-17 Polyactiva Pty Ltd. Biodegradable polymer—bioactive moiety conjugates
WO2010040187A1 (en) 2008-10-10 2010-04-15 The Bionic Ear Institute Polymer-bioactive agent conjugates
EP2355853B1 (en) * 2008-10-10 2016-12-07 Polyactiva Pty Ltd Biodegradable polymer - bioactive moiety conjugates
US8680050B2 (en) 2009-02-03 2014-03-25 Amunix Operating Inc. Growth hormone polypeptides fused to extended recombinant polypeptides and methods of making and using same
BR122021021381B1 (pt) 2009-02-03 2023-05-16 Amunix Pharmaceuticals, Inc Método de aprimoramento de uma propriedade de uma proteína biologicamente ativa
US8703717B2 (en) 2009-02-03 2014-04-22 Amunix Operating Inc. Growth hormone polypeptides and methods of making and using same
US9849188B2 (en) 2009-06-08 2017-12-26 Amunix Operating Inc. Growth hormone polypeptides and methods of making and using same
US8841249B2 (en) 2009-08-06 2014-09-23 Novo Nordisk A/S Growth hormones with prolonged in-vivo efficacy
CN101831067A (zh) * 2010-05-31 2010-09-15 王二新 聚乙二醇脂类缀合物及其在制备药物中的应用
EP2446898A1 (en) 2010-09-30 2012-05-02 Laboratorios Del. Dr. Esteve, S.A. Use of growth hormone to enhance the immune response in immunosuppressed patients
CN102367290B (zh) * 2011-04-26 2013-05-08 厦门赛诺邦格生物科技有限公司 链官能化的多级支化聚乙二醇及其合成方法
WO2014110867A1 (zh) * 2013-01-17 2014-07-24 厦门赛诺邦格生物科技有限公司 一种单一官能化的支化聚乙二醇及其修饰的生物相关物质
CN104877127B (zh) 2015-06-23 2017-11-10 厦门赛诺邦格生物科技股份有限公司 一种八臂聚乙二醇衍生物、制备方法及其修饰的生物相关物质
MY191506A (en) 2014-11-06 2022-06-28 Pharmaessentia Corp Dosage regimen for pegylated interferon
US11518781B2 (en) 2017-12-29 2022-12-06 Hoffmann-La Roche Inc. Process for providing PEGylated protein composition
US20200362002A1 (en) * 2017-12-29 2020-11-19 Hoffmann-La Roche Inc. Process for providing pegylated protein composition
US20200323993A1 (en) * 2017-12-29 2020-10-15 Hoffmann-La Roche Inc. Process for providing pegylated protein composition

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993000109A1 (en) * 1991-06-28 1993-01-07 Genentech, Inc. Method of stimulating immune response using growth hormone
JP3092531B2 (ja) * 1996-11-05 2000-09-25 日本油脂株式会社 コハク酸イミジル基置換ポリオキシアルキレン誘導体の製造方法
DE69838552T2 (de) * 1997-07-14 2008-05-21 Bolder Biotechnology, Inc., Louisville Derivate des wachstumshormons und verwandte proteine
JP3921781B2 (ja) * 1998-02-12 2007-05-30 日本油脂株式会社 カルボキシル基含有ポリオキシアルキレン化合物
EP2305804B1 (en) * 1999-01-14 2015-05-06 Bolder Biotechnology, Inc. MonoPEGylated human growth hormone
HUP0500997A2 (en) * 2001-11-20 2007-11-28 Pharmacia Corp Chemically-modified human growth hormone conjugates
ES2897470T3 (es) * 2002-09-09 2022-03-01 Nektar Therapeutics Alcanales poliméricos solubles en agua
JP4412461B2 (ja) * 2002-11-20 2010-02-10 日油株式会社 修飾された生体関連物質、その製造方法および中間体
EP1581260B1 (en) * 2002-12-31 2014-09-17 Nektar Therapeutics Polymeric reagents comprising a ketone or a related functional group
WO2005000360A2 (en) * 2003-05-23 2005-01-06 Nektar Therapeutics Al, Corporation Peg derivatives having an amidocarbonate linkage

Also Published As

Publication number Publication date
TNSN07078A1 (fr) 2008-06-02
CN101010105A (zh) 2007-08-01
ECSP077281A (es) 2007-03-29
MA28908B1 (fr) 2007-10-01
AP2007003919A0 (en) 2007-02-28
IL181085A0 (en) 2007-07-04
MX2007002441A (es) 2007-05-04
CA2577999A1 (en) 2006-03-09
TW200621291A (en) 2006-07-01
EP1789092A2 (en) 2007-05-30
GT200500235A (es) 2006-03-21
UY29088A1 (es) 2006-03-31
NL1029828A1 (nl) 2006-03-01
CR8942A (es) 2007-08-16
ZA200701802B (en) 2008-08-27
WO2006024953A2 (en) 2006-03-09
JP2008511610A (ja) 2008-04-17
NO20071322L (no) 2007-05-29
BRPI0515118A (pt) 2008-07-01
AU2005278903A1 (en) 2006-03-09
NL1029828C2 (nl) 2006-10-20
KR20070042567A (ko) 2007-04-23
PE20060654A1 (es) 2006-08-12
WO2006024953A3 (en) 2007-01-18
EA200700380A1 (ru) 2007-10-26

Similar Documents

Publication Publication Date Title
AR050851A1 (es) Conjugados de hormona del crecimiento humana y polietilenglicol ramificado con glicerol, proceso para su preparacion y metodos de uso de los mismos
AR047928A1 (es) Derivados de tetrahidropiridoindol
CL2011002430A1 (es) Variante de peptido natriuretico de tipo c (cnp); composicion farmaceutica que la comprende; metodo de produccion, celula huesped y uso de dicha variante.
ECSP10010684A (es) Agonistas mezclados, basados en gip para el tratamiento de trastornos metabólicos y obesidad.
UY27720A1 (es) Aroilpiridinonas monocíclicas,
WO2007059979A3 (en) Allergy treatment by epicutaneous allergen administration
AR048878A1 (es) Composiciones topicas de metadona y metodos para usarlas
AR069903A1 (es) Conjugado anticuerpo- molecula asociada dirigidos a la proteina tirosina quinasa 7 (ptk 7), composicion farmaceutica que lo comprende, acido nucleico, factor de expresion y celula huesped relacionados y su uso para preparar un medicamento util para el tratamiento o prevencion de cancer
AR069830A1 (es) Factor viii y factor de von willebrand recombinantes modificados y metodos de uso de los mismos
BR0313343A (pt) Uso de uma mistura de agentes permeantes, soluções para aplicação ungueal e periungueal e uso de uma solução para aplicação ungueal e periungueal
AR053651A1 (es) Tratamiento combinado de anticuerpo antictla4 r inhibidor de aromatasa para el cancer de mama
GT200500237A (es) Derivados de pirimidina
CY1111177T1 (el) Ενωση φαινοθειαζινιου για επουλωση τραυματων
CL2007001166A1 (es) Compuestos derivados de pirimidina condensada, inhibidores de pi3-quinasa; procesos para preparar los compuestos; composicion farmaceutica que los comprende; uso de los compuestos en la preparacion de medicamentos; proceso para preparar la composicion farmaceutica; y kit que incluye a la composicion farmaceutica
EA201370006A1 (ru) Местная фармацевтическая композиция, содержащая флурбипрофен
CO6280470A2 (es) Bis-piridilpiridonas como antaginistas del receptor 1 de la hormona concentradora de la melanina
EA200701228A1 (ru) Стабильные композиции фенофибрата с эфирами жирных кислот
AR077611A1 (es) Metodo y conjunto de elementos ( kit) para tratar la adiccion a la nicotina. combinacion. uso.
ECSP067074A (es) Derivados de 4-fenil-pirimidina-2-carbonitrilo
BR112012015437A2 (pt) composição tópica substancialmente anidra de armazenamento estável
PE20212158A1 (es) Composicion farmaceutica acuosa de anticuerpo anti-il17a y su uso
AR048672A1 (es) Tabletas de desintegracion que comprenden licarbazepina
BRPI0517782A (pt) formulações de benzotiazol e uso das mesmas
DOP2005000172A (es) Conjugados de hormonas del crecimiento humana y polietilenglicol ramificado con glicerol, proceso para su preparacion y metodo de uso de los mismos
CY1112134T1 (el) Φαρμακευτικες συνθεσεις που περιεχουν ανταγωνιστες βραδυκινινης και υαλουρονικο οξυ και χρησεις αυτων

Legal Events

Date Code Title Description
FB Suspension of granting procedure